These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33627502)

  • 1. Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models.
    Jones CJ; Subramaniam M; Emch MJ; Bruinsma ES; Ingle JN; Goetz MP; Hawse JR
    Mol Cancer Res; 2021 Jun; 19(6):1026-1039. PubMed ID: 33627502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
    Jayaraman S; Hou X; Kuffel MJ; Suman VJ; Hoskin TL; Reinicke KE; Monroe DG; Kalari KR; Tang X; Zeldenrust MA; Cheng J; Bruinsma ES; Buhrow SA; McGovern RM; Safgren SL; Walden CA; Carter JM; Reid JM; Ingle JN; Ames MM; Hawse JR; Goetz MP
    Breast Cancer Res; 2020 May; 22(1):51. PubMed ID: 32430040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.
    Maximov PY; McDaniel RE; Fernandes DJ; Bhatta P; Korostyshevskiy VR; Curpan RF; Jordan VC
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25258390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens.
    Hawse JR; Subramaniam M; Cicek M; Wu X; Gingery A; Grygo SB; Sun Z; Pitel KS; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC
    PLoS One; 2013; 8(1):e54613. PubMed ID: 23382923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
    Busonero C; Leone S; Bianchi F; Acconcia F
    Cell Oncol (Dordr); 2018 Dec; 41(6):677-686. PubMed ID: 30182339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
    Kim SS; Lee MH; Lee MO
    Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen metabolites treatment promotes ERα+ transition to triple negative phenotype in vitro, effects of LDL in chemoresistance.
    Muñoz-Ayala A; Chimal-Vega B; Serafín-Higuera N; Galindo-Hernández O; Ramírez-Rosales G; Córdova-Guerrero I; Gómez-Lucas LF; García-González V
    Biosci Rep; 2024 Aug; 44(8):. PubMed ID: 39034849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells.
    Shaw LE; Sadler AJ; Pugazhendhi D; Darbre PD
    J Steroid Biochem Mol Biol; 2006 Apr; 99(1):19-32. PubMed ID: 16533599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.
    Wu X; Subramaniam M; Grygo SB; Sun Z; Negron V; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC; Hawse JR
    Breast Cancer Res; 2011 Mar; 13(2):R27. PubMed ID: 21392396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
    Lim YC; Li L; Desta Z; Zhao Q; Rae JM; Flockhart DA; Skaar TC
    J Pharmacol Exp Ther; 2006 Aug; 318(2):503-12. PubMed ID: 16690721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
    Fernandez-Cuesta L; Anaganti S; Hainaut P; Olivier M
    Int J Cancer; 2011 Apr; 128(8):1813-21. PubMed ID: 20549698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
    Lim YC; Desta Z; Flockhart DA; Skaar TC
    Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
    Xiong H; Jin X; You C
    Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
    Thewes V; Simon R; Schroeter P; Schlotter M; Anzeneder T; Büttner R; Benes V; Sauter G; Burwinkel B; Nicholson RI; Sinn HP; Schneeweiss A; Deuschle U; Zapatka M; Heck S; Lichter P
    Cancer Res; 2015 Feb; 75(4):720-31. PubMed ID: 25643697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of UDP-glucuronosyltransferase 2B15 gene expression by the major active metabolites of tamoxifen, 4-hydroxytamoxifen and endoxifen, in breast cancer cells.
    Chanawong A; Hu DG; Meech R; Mackenzie PI; McKinnon RA
    Drug Metab Dispos; 2015 Jun; 43(6):889-97. PubMed ID: 25795461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.
    Maximov PY; McDaniel RE; Fernandes DJ; Korostyshevskiy VR; Bhatta P; Mürdter TE; Flockhart DA; Jordan VC
    Br J Pharmacol; 2014 Dec; 171(24):5624-35. PubMed ID: 25073551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
    Wu X; Hawse JR; Subramaniam M; Goetz MP; Ingle JN; Spelsberg TC
    Cancer Res; 2009 Mar; 69(5):1722-7. PubMed ID: 19244106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells.
    Zhou Q; Zeng H; Ye P; Shi Y; Guo J; Long X
    Anticancer Drugs; 2018 Jul; 29(6):539-548. PubMed ID: 29557813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.